{"id":405,"date":"2011-05-24T16:06:52","date_gmt":"2011-05-24T21:06:52","guid":{"rendered":"http:\/\/dev.testing.com\/?page_id=405"},"modified":"2011-05-24T16:06:52","modified_gmt":"2011-05-24T21:06:52","slug":"prometheus-announces-agreement-to-be-acquired-by-nestle-health-science","status":"publish","type":"post","link":"https:\/\/splitrock.com\/?p=405","title":{"rendered":"Prometheus Announces Agreement to be Acquired by Nestl\u00e9 Health Science"},"content":{"rendered":"\n<p>Prometheus Announces Agreement to be Acquired by Nestl\u00e9 Health Science <\/p>\n<p>San Diego, <b>May 24, 2011<\/b> \u2013 Prometheus Laboratories Inc., (\u201cPrometheus\u201d) a specialty pharmaceutical and diagnostic company, today announced that it has entered into a definitive agreement to be acquired by Nestl\u00e9 Health Science S.A., a wholly-owned subsidiary of Nestl\u00e9 S.A., for an undisclosed amount. <\/p>\n<p>Nestl\u00e9 Health Science became operational in January 2011 with the goal of pioneering science-based nutritional solutions in order to deliver improved personalized healthcare for medical conditions. In the longer term, the company aims to use nutritional solutions to change the healthcare paradigm and deliver affordable and effective health benefits which are also safe and sustainable. <\/p>\n<p>Prometheus\u2019 capabilities strongly support Nestl\u00e9 Health Science\u2019s ambition of pioneering science-based nutritional solutions to deliver improved personalized healthcare for medical conditions. <\/p>\n<p>\u201cThis is a strategic move into gastrointestinal diagnostics. Prometheus\u2019s leading edge diagnostics technology and outstanding sales force will help us to develop an integrated approach to personalized healthcare,\u201d said Luis Cantarell, Nestl\u00e9 Health Science President and Chief Executive Officer. \u201cIt is fully consistent with our vision of pioneering science-based nutritional solutions to deliver improved personalized healthcare for medical conditions.\u201d <\/p>\n<p>\u201cWe are delighted to join Nestl\u00e9 Health Science, and we share their commitment to personalized healthcare. With Nestl\u00e9 Health Science\u2019s support, we will accelerate the development of our innovative diagnostic platforms for gastroenterology and oncology and potentially into additional important therapeutic areas,\u201d said Joseph M. Limber, Prometheus President &amp; Chief Executive Officer.  \u201cWe also intend to leverage Nestl\u00e9 Health Science\u2019s nutritional product offerings and geographic presence to expand our successful Rx\/Dx business model into a Dx\/Nx\/Rx model.\u201d <\/p>\n<p>Prometheus\u2019s strong expertise and research and development in gastrointestinal and oncology diagnostics will accelerate the research program that is being established in the newly-created Nestl\u00e9 Institute of Health Sciences.  It will create new opportunities for developing personalized nutrition strategies that will help in the management and prevention of chronic health conditions.  The research and development pipeline will encompass other areas of strategic interest for Nestl\u00e9 Health Science, such as metabolic conditions, brain health and oncology. <\/p>\n<p>Prometheus was founded in 1995 and has had the support of institutional ownership including DLJ Merchant Banking Partners, SPVC (managed by Split Rock Partners), Sprout Group (sub-advised by New Leaf Venture Partners), Apax Partners, Pamlico Capital and Brentwood Venture Capital. The transaction is conditioned upon the tender of at least a majority of the shares of Prometheus in the tender offer, receipt of regulatory approvals and other customary closing conditions. The transaction is expected to close early in the third quarter of this year. <\/p>\n<p>Goldman Sachs is serving as financial advisor to Prometheus and Latham &amp; Watkins LLP is serving as Prometheus&#8217; legal advisor. <\/p>\n<p><b>About Prometheus<\/b><br \/> Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus\u2019 corporate offices are located in San Diego, California. For more information about Prometheus, please visit <a href=\"http:\/\/www.prometheuslabs.com\">www.prometheuslabs.com<\/a>. <\/p>\n<p><b>About Nestl\u00e9 Health Science <\/b><br \/> Nestl\u00e9 Health Science S.A., a fully-owned subsidiary of Nestl\u00e9 S.A., is operational since January 1, 2011. Through its businesses Nestl\u00e9 HealthCare Nutrition, Vitaflo and CM&amp;D Pharma Ltd., Nestl\u00e9 Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. For more information about Nestl\u00e9 Health Science, please visit <a href=\"http:\/\/www.nestlehealthscience.com\">www.nestlehealthscience.com<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prometheus Laboratories Inc. today announced that it has entered into a definitive agreement to be acquired by Nestl\u00e9 Health Science S.A. for an undisclosed amount.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_vp_format_video_url":"","_vp_image_focal_point":[],"footnotes":""},"categories":[32],"tags":[],"class_list":["post-405","post","type-post","status-publish","format-standard","hentry","category-portfolio-company-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/splitrock.com\/index.php?rest_route=\/wp\/v2\/posts\/405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/splitrock.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/splitrock.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/splitrock.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/splitrock.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=405"}],"version-history":[{"count":0,"href":"https:\/\/splitrock.com\/index.php?rest_route=\/wp\/v2\/posts\/405\/revisions"}],"wp:attachment":[{"href":"https:\/\/splitrock.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/splitrock.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/splitrock.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}